IN8bio (INAB) News Today → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free INAB Stock Alerts $1.03 +0.01 (+0.98%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | americanbankingnews.comIN8bio (NASDAQ:INAB) Price Target Cut to $12.50May 14, 2024 | globenewswire.comIN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressMay 13, 2024 | globenewswire.comIN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024May 13, 2024 | americanbankingnews.comHC Wainwright Comments on IN8bio, Inc.'s Q1 2025 Earnings (NASDAQ:INAB)May 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for IN8bio Amid Promising Clinical Trials and Strong PipelineMay 10, 2024 | msn.comIN8bio GAAP EPS of -$0.20 misses by $0.03May 10, 2024 | investorplace.comINAB Stock Earnings: IN8bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.comIN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsApril 30, 2024 | globenewswire.comIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaApril 24, 2024 | globenewswire.comIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingApril 22, 2024 | finance.yahoo.comINAB: Initiating Coverage – Enhancing the Insurgents of the Immune SystemApril 16, 2024 | globenewswire.comIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 12, 2024 | markets.businessinsider.comPromising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR PlatformApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)April 10, 2024 | msn.comKill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows PotentialApril 9, 2024 | globenewswire.comIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024March 28, 2024 | finance.yahoo.comWe're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn RateMarch 20, 2024 | investing.comLaidlaw sets INAB stock to buy, targets $7.50 priceMarch 14, 2024 | investorplace.comINAB Stock Earnings: IN8bio Misses EPS for Q4 2023March 14, 2024 | globenewswire.comIN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsMarch 13, 2024 | markets.businessinsider.comBuy Recommendation Based on IN8bio’s Promising γ δ T Cell Therapy Developments and Positive Clinical Trial OutcomesMarch 5, 2024 | globenewswire.comIN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024February 26, 2024 | businesswire.comIN8bio to Present at Upcoming Investor ConferencesFebruary 14, 2024 | finanznachrichten.deIN8bio, Inc: IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 14, 2024 | finance.yahoo.comIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 14, 2024 | globenewswire.comIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)January 4, 2024 | msn.comIn8bio stock jumps 11% following clinical updateJanuary 4, 2024 | finance.yahoo.comIN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline GoalsDecember 18, 2023 | ca.finance.yahoo.comIN8bio, Inc. (INAB) Stock Price, News, Quote & History - Yahoo FinanceDecember 14, 2023 | markets.businessinsider.comBuy Rating for IN8bio Amidst Promising Leukemia Treatment Advances and Robust Clinical DataDecember 11, 2023 | finance.yahoo.comIN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private PlacementDecember 7, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio Appoints Dr. Corinne Epperly to Board of DirectorsDecember 7, 2023 | finance.yahoo.comIN8bio Appoints Dr. Corinne Epperly to Board of DirectorsDecember 5, 2023 | finance.yahoo.comIN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with LeukemiaNovember 28, 2023 | finance.yahoo.comHarnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio’s Innovative ApproachNovember 23, 2023 | finance.yahoo.comHere's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom FisherNovember 20, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaNovember 20, 2023 | finance.yahoo.comIN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed GlioblastomaNovember 15, 2023 | markets.businessinsider.comPromising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative DevelopmentsNovember 10, 2023 | finance.yahoo.comIN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual MeetingNovember 9, 2023 | msn.comIN8bio GAAP EPS of -$0.23November 9, 2023 | finance.yahoo.comIN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | morningstar.comIN8bio Inc Ordinary Shares INABNovember 6, 2023 | finance.yahoo.comHow IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The PastNovember 2, 2023 | tmcnet.comIN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual MeetingNovember 1, 2023 | finance.yahoo.comIN8bio to Participate at the 2023 Truist Securities BioPharma SymposiumOctober 13, 2023 | markets.businessinsider.comBuy Recommendation for IN8bio: Anticipated Funding, Clinical Validation, and Key Developments Drive Positive OutlookSeptember 29, 2023 | markets.businessinsider.comAnalyst Maintains Buy Rating for IN8bio Based on Positive SITC Release and Promising R&D DevelopmentsSeptember 29, 2023 | finance.yahoo.comIN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond INAB Media Mentions By Week INAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INAB News Sentiment▼0.310.42▲Average Medical News Sentiment INAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INAB Articles This Week▼81▲INAB Articles Average Week Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYTH News Today DYAI News Today OKYO News Today QNCX News Today HCWB News Today SABS News Today ACHL News Today TARA News Today INKT News Today SRZN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INAB) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
